ER
ABBV icon

Enlightenment Research’s AbbVie ABBV Stock Holding History

Enlightenment Research’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,879
Closed -$467K – 98
2022
Q1 		$467K Buy
+2,879
New +$418K 0.62% 49
2021
Q3 		– Sell
-3,700
Closed -$417K – 130
2021
Q2 		$417K Buy
+3,700
New +$417K 0.53% 54
2020
Q1 		– Sell
-3,768
Closed -$334K – 165
2019
Q4 		$334K Buy
+3,768
New +$313K 1.56% 22
2019
Q3 		– Sell
-8,500
Closed -$675K – 94
2019
Q2 		$675K Buy
+8,500
New +$668K 0.34% 81

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Enlightenment Research's ABBV Position: Q2 2022 in Review

Enlightenment Research sold out of AbbVie (ABBV) in Q2 2022, closing a stake of 2,879 shares — an estimated $467K sold.

Enlightenment Research first reported a position in ABBV in Q2 2019 and held it in 4 quarters. The position peaked at $675K in Q2 2019. 3,005 funds tracked by Wall St. Rank hold ABBV as of Q2 2022.

  • Enlightenment Research reported no remaining AbbVie position as of Q2 2022 after selling out during the quarter.
  • Enlightenment Research sold 2,879 AbbVie shares in Q2 2022, an estimated $467K.
  • Enlightenment Research first reported a position in AbbVie in Q2 2019 and held it in 4 quarters.
  • Enlightenment Research's AbbVie position peaked at $675K in Q2 2019.
  • 3,005 funds tracked by Wall St. Rank held AbbVie as of Q2 2022.

Based on Enlightenment Research's 13F filing for Q2 2022, filed 12 Aug 2022.